Member Info for Danielm89

🤣🤣🤣

The present invention also provides an anticancer drug for use in treating cancer wherein the subject has been identified as having cancer by the method of the invention.

The present invention further provides an anticancer lung cancer drug for use in treating lung cancer wherein the subject has been identified as having lung cancer by the method of the invention.

🧐

The Ciz1 b-variant may be detected in a sample from a subject, for example a blood, urine, saliva or bronchoalveolar lavage sample.

Saliva 🤔

Excess expression of either the replication or immobilisation domain of Ciz1 has also been demonstrated in cancers, for example in NSCLC, breast, colon, kidney, liver, bladder and thyroid cancers. A correlation of domain expression with the stage of the cancer has also been determined (see WO 2012/078208).

Hello… how many cancers?

Https://patents.justia.com/patent/20230266327

US patent filed and published already 23rd august

“ Our CEO and Chairman, Allan Syms, has been invited by the British Embassy to present at a Sino-UK Investor roadshow as part of the China BioMed Innovation and Investment Conference in #Suzhou. The invite comes off the back of our recent developments and partnerships.

We recently announced a successful evaluation programme with Bio-Techne, a Life Science and Clinical Diagnostics Research organisation with a huge global presence. We believe Bio-Techne’s platform will be important in developing high throughput sensitive early cancer detection laboratory tests.”

I was mega stressed as my youngest was trying to climb a ladder bed whilst the eldest was picking buttons off a pretend laptop.

Genuinely no ill intent, nothing but love 👍 it’s good to analyse things from different views keeps us grounded

Variation to the 500k… 350k

The allotted shares included the brokers 17k fee (one off payment) so going forward (if they use it again) it’ll be 16m shares (I suspect they won’t)

Sorry for the perceived aggression it wasn’t my intent, I was in ikea and had my 2 kids dangling off me.

“The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.”

· Successful development of additional specific monoclonal antibodies for CIZ1B Biomarker

· Application to a new high-throughput immunoassay platform.

During this period the team at the University of York under the direction of Professor Dawn Coverley has successfully isolated and validated an additional panel of specific monoclonal antibodies for the CIZ1B biomarker, which is highly associated with early stage lung cancer.

A major breakthrough by the team at the University of York has significantly improved on this traditional approach using alternative high-throughput assay formats for CIZ1B, that will now be used as the basis for a commercial product.

They have…. Do you even read RNS? Or are you short? First you quote the drawdown wrong (amount and shares) now you’re claiming we aren’t on the next stage.

READ THE RNS

It’s been 46 days as of Monday 👀

“ The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.”

10th august RNS

Terms of the deal

The deal is good from Cizzle’s perspective, because it promotes the development of its CIZ1b-based diagnostic test for lung cancer at little cost to the company, secures supply agreements for monoclonal antibodies and reagents used in the test, and will bring future royalties on sales.

► The partners are responsible for funding all activities in China, including the development, clinical trials, manufacturing of commercial test kits, and distribution of the product.

► Initial development will commence within 60 days of Cizzle supplying the immunoreagents to its partners in China.

► Cizzle will supply, and be paid for, all the monoclonal antibodies and reagents used in the test, for security and quality control.

► Cizzle is to receive a 10% royalty on net sales of all products and services using its proprietary CIZ1b technology.

Department

A technician role in the Department of Biology at York supporting a project to develop molecular tools to detect the lung cancer biomarker CIZ1B

Role

The role will involve daily maintenance of cultured cells and associated facilities, including supply of stock materials and production logs, regular liaison with project manager, and will involve working with human blood samples. The role holder will be taught methods to purify and validate monoclonal antibodies and will then apply methods routinely. The role is funded by Cizzle Biotechnology to progress its assay development work, but the role holder will also be an integrated member of a laboratory team studying CIZ1 biology and will be expected to contribute to other laboratory tasks as needed.

Skills, Experience & Qualification Needed

The role holder will have HNC, HND, Degree, or equivalent experience. They will have hands-on experience of mammalian cell culture techniques and the rigorous maintenance of laboratory records.

Interview date: 15-09-23

I’m well aware of how it works mr bloggs 🤣

Cizzle is developing a commercial test based on the CIZ1b biomarker, having successfully developed a prototype test on very limited resources.

► Much of the elucidation and understanding of CIZ1 in the early years was undertaken with grant funding.

► R&D investment will ramp up when appropriate funding is in place, although the requirements have changed with the signed licensing deals and the expanded contract with the University of York to include other cancers.

could be going commercial next fewmonth and clinical trials, employed more scientists recently so will probably be developing the breast and ovary tests.

Can also start the companion test for AstraZeneca “for which they get an extra £1m”

“R&d will ramp up when appropriate funding is in place”

They now have more than appropriate funding given the put options to CIZ is $11.5… $3.25m is over 3 years cash runway

No ridiculous placings (look at FAB, PYC and APTA)

Find it a bit weird you quote the RNS but inflate the numbers significantly 🤔

Conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p

“Conditionally” it’ll get cancelled, we might see how much if any has been used in the intrims. Murph closed at $20 so ciZ currently up 90% on their investment. But that’s all it was … an investment

Next up clinical trails …..

“CIZ1b level in individuals without diagnosed tumours established a threshold that correctly classified 98% of small cell lung cancers (SCLC) and non-SCLC patients (receiver operator characteristic AUC 0.958). Within set 2, comparison of stage 1 non-SCLC with asymptomatic age-matched smokers, or individuals with benign lung nodules, correctly classified 95% of patients“

It’s £350,000 not £500,000

MURF $18 pre market $3.75m is $6.2m as it stands

The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.

The China partners will be solely responsible for funding all activities in China including development, clinical trials, manufacturing, and distribution. It is intended that initial development will commence within 60 days of Cizzle Biotechnology supplying its immunoreagents to the China partners,

It’s been 40 days

Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:

"This agreement represents a significant opportunity to bring early and cost-effective cancer detection to the people of China. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about £100 per test, the total available market for tests based on the CIZ1B biomarker would be £3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion). We have already secured strong interest from our nationwide network of national clinical centers and key opinion leaders because of the promising results using the CIZ1B biomarker for lung cancer early detection in the UK and one our first tasks is to commence pilot studies at the Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Centre, and Beijing Cancer Hospital, affiliated with Peking University."